miR-21-3p/IL-22 Axes Are Major Drivers of Psoriasis Pathogenesis by Modulating Keratinocytes Proliferation-Survival Balance and Inflammatory Response.
IL-22
keratinocytes
miR-21-3p
miR-21-5p
proliferation
psoriasis
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
26 09 2021
26 09 2021
Historique:
received:
13
08
2021
revised:
17
09
2021
accepted:
23
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Psoriasis is a chronic inflammatory skin disease that is mediated by complex crosstalk between immune cells and keratinocytes (KCs). Emerging studies have showed a specific psoriatic microRNAs signature, in which miR-21 is one of the most upregulated and dynamic miRNAs. In this study, we focused our investigations on the passenger miR-21-3p strand, which is poorly studied in skin and in psoriasis pathogenesis. Here, we showed the upregulation of miR-21-3p in an IMQ-induced psoriasiform mouse model. This upregulation was correlated with IL-22 expression and functionality, both in vitro and in vivo, and it occurred via STAT3 and NF-κB signaling. We identified a network of differentially expressed genes involved in abnormal proliferation control and immune regulatory genes implicated in the molecular pathogenesis of psoriasis in response to miR-21-3p overexpression in KCs. These results were confirmed by functional assays that validated the proliferative potential of miR-21-3p. All these findings highlight the importance of miR-21-3p, an underestimated miRNA, in psoriasis and provide novel molecular targets for therapeutic purposes.
Identifiants
pubmed: 34685526
pii: cells10102547
doi: 10.3390/cells10102547
pmc: PMC8534095
pii:
doi:
Substances chimiques
Interleukins
0
MIRN21 microRNA, mouse
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Lancet. 2007 Jul 21;370(9583):263-271
pubmed: 17658397
Curr Opin Cell Biol. 2003 Apr;15(2):158-63
pubmed: 12648671
Silence. 2012 Jan 09;3(1):1
pubmed: 22230293
Cancer Cell. 2011 Nov 15;20(5):635-48
pubmed: 22094257
Immunol Rev. 2012 Mar;246(1):125-40
pubmed: 22435551
PLoS One. 2011;6(6):e20916
pubmed: 21687694
Cell. 2003 Oct 17;115(2):209-16
pubmed: 14567918
EMBO Mol Med. 2016 Aug 01;8(8):919-36
pubmed: 27250636
Dermatol Ther (Heidelb). 2021 Oct;11(5):1551-1569
pubmed: 34260044
Int Immunopharmacol. 2004 May;4(5):679-91
pubmed: 15120652
J Biol Chem. 2012 Jun 22;287(26):21783-95
pubmed: 22547075
PLoS One. 2010 Jun 30;5(6):e11387
pubmed: 20613982
Mol Neurodegener. 2018 Oct 17;13(1):56
pubmed: 30333037
Sci Transl Med. 2014 Feb 26;6(225):225re1
pubmed: 24574341
Acta Derm Venereol. 2019 Feb 1;99(2):196-205
pubmed: 30320872
Int J Clin Exp Pathol. 2015 May 01;8(5):4555-63
pubmed: 26191145
Oncogene. 2005 Apr 18;24(17):2810-26
pubmed: 15838517
Blood. 2009 Jun 25;113(26):6603-10
pubmed: 19411637
Oncotarget. 2016 Jun 14;7(24):36321-36337
pubmed: 27166999
Blood. 2007 Aug 15;110(4):1330-3
pubmed: 17496199
Crit Rev Eukaryot Gene Expr. 2010;20(2):141-8
pubmed: 21133843
Sci Rep. 2016 Sep 06;6:28281
pubmed: 27596120
J Dermatol. 2020 Jul;47(7):735-742
pubmed: 32396270
Nat Med. 2005 Jan;11(1):43-9
pubmed: 15592573
J Immunol. 2012 Jan 1;188(1):462-9
pubmed: 22131335
Lancet. 2021 Feb 6;397(10273):475-486
pubmed: 33549192
J Dermatol Sci. 2010 Jun;58(3):177-85
pubmed: 20417062
Nucleic Acids Res. 2007;35(17):5944-53
pubmed: 17726050
N Engl J Med. 2021 Jul 8;385(2):142-152
pubmed: 33891380
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):9818-9820
pubmed: 30201723
J Mol Med (Berl). 2009 May;87(5):523-36
pubmed: 19330474
J Dermatol Sci. 2003 Feb;31(1):65-71
pubmed: 12615366
Eur J Immunol. 2006 May;36(5):1309-23
pubmed: 16619290
J Allergy Clin Immunol. 2017 Oct;140(4):1191-1194.e4
pubmed: 28532655
Biochem Soc Trans. 2014 Aug;42(4):1135-40
pubmed: 25110015
J Gene Med. 2009 May;11(5):401-11
pubmed: 19326361
Nucleic Acids Res. 2013 Nov;41(20):e192
pubmed: 24013565
Nat Rev Immunol. 2009 Oct;9(10):679-91
pubmed: 19763149
PLoS One. 2014 Sep 10;9(9):e107467
pubmed: 25208211
Mediators Inflamm. 2018 Nov 26;2018:1756494
pubmed: 30598636
PLoS One. 2015 Mar 23;10(3):e0121547
pubmed: 25799148
Annu Rev Immunol. 2014;32:227-55
pubmed: 24655295
J Invest Dermatol. 1999 Apr;112(4):426-31
pubmed: 10201524
PLoS One. 2007 Jul 11;2(7):e610
pubmed: 17622355
Exp Dermatol. 2012 Apr;21(4):312-4
pubmed: 22417311
Nat Commun. 2015 Jul 03;6:7652
pubmed: 26138368
J Lipid Res. 2015 Jan;56(1):38-50
pubmed: 25327529
Br J Dermatol. 2017 Mar;176(3):650-658
pubmed: 27579733
Mediators Inflamm. 2017;2017:5095293
pubmed: 29180836
Exp Dermatol. 2019 Nov;28(11):1336-1340
pubmed: 31278779
Cell. 2003 Oct 17;115(2):199-208
pubmed: 14567917
Immunol Rev. 2010 Nov;238(1):93-109
pubmed: 20969587
J Immunol. 2005 Mar 15;174(6):3695-702
pubmed: 15749908
Cell Rep. 2019 May 7;27(6):1742-1754.e6
pubmed: 31067460
J Biol Chem. 1994 Jan 21;269(3):2016-22
pubmed: 7904998
J Biol Chem. 2008 Nov 28;283(48):33554-62
pubmed: 18826952
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Am J Clin Dermatol. 2021 Mar;22(2):173-192
pubmed: 33301128
Cytokine Growth Factor Rev. 2010 Feb;21(1):11-9
pubmed: 20018552
Protein Cell. 2018 Dec;9(12):1027-1038
pubmed: 29508278
J Immunol Res. 2019 Sep 10;2019:2546161
pubmed: 31583255
Int J Mol Sci. 2016 Jun 24;17(7):
pubmed: 27347933
Lancet. 2021 Feb 6;397(10273):487-498
pubmed: 33549193
Nat Cell Biol. 2009 Mar;11(3):228-34
pubmed: 19255566
J Invest Dermatol. 2005 Jun;124(6):1275-83
pubmed: 15955104
Am J Pathol. 2012 Dec;181(6):1911-20
pubmed: 23159215
Biomarkers. 2014 Nov;19(7):590-6
pubmed: 25174622
J Clin Invest. 2009 Dec;119(12):3573-85
pubmed: 19920355